Regulatory approval

Published by the Health Canada. Approved

VECTIBIX (panitumumab for injection) is indicated as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

This is written in the approval document.

Citation

Amgen Canada Inc. Vectibix (panitumumab)[product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063326.PDF. Revised October 2021. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals